← Encyclopedia

A regulatory pathway letting patients access an unapproved drug outside a clinical trial, typically for serious conditions with no other options.

Example: Germany's BfArM approved what's reportedly the EU's first compassionate-use psilocybin program in 2026 — see our coverage of how narrow that access actually is.